|
Amyloidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
When using the core CSF biomarkers (Aβ42, total Tau and phosphorylated Tau), 30% of the patients fell into the high-AD-likelihood (HL) group (both amyloid and neurodegeneration markers positive), 30% into the low-AD-likelihood group (all biomarkers negative), 28% into the suspected non-Alzheimer pathophysiology (SNAP) group (only neurodegeneration markers positive) and 12% into the isolated amyloid pathology group (only amyloid-positive).
|
29558986 |
2018 |
|
MYELOPROLIFERATIVE DISORDER, CHRONIC, WITH EOSINOPHILIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
When SPMC-CM and EMP PF were immunodepleted with GM-CSF antibody, PMN apoptosis was significantly higher.
|
12645855 |
2003 |
|
Leukemia, Myelocytic, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
When OCI/AML-4 cells are exposed to MGF with IL-3 or GM-CSF, additive or synergistic effects are seen.
|
1715961 |
1991 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When immunized five times with plasmid DNA encoding secErbB-2 and GM-CSF, respectively, approximately 33% of the Her-2 Tg mice rejected a lethal challenge of EL-4/E2 tumor cells, whereas all immunized littermates rejected the tumor.
|
14634087 |
2003 |
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
When Cognitive Decline and Depression Coexist in the Elderly: CSF Biomarkers Analysis Can Differentiate Alzheimer's Disease from Late-Life Depression.
|
29527163 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We will include any study assessing the diagnostic and prognostic role of CSF biomarkers in PD.
|
29170290 |
2017 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We will be recruiting male and female participants aged >60 years with prodromal AD, defined as absence of dementia but with evidence of cognitive impairment together with AD pathology as assessed using PET imaging or CSF biomarkers.
|
30904851 |
2019 |
|
Pseudotumor Cerebri
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used the clinically provided Friedman classification 13/31 patients with definite PTCS (group A), 13/31 with probable PTCS (group B), and 5/31 not PTCS (group C), to compare CSF dynamics in the 3 groups.
|
31325030 |
2020 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used stepwise logistic regression analyses to test whether neurofilament contributes to a biomarker CSF panel including total, oligomeric, and phosphorylated α-synuclein and Alzheimer's disease biomarkers.
|
31737952 |
2020 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used linear regression, which included imaging and clinical measures (age, duration, education, gender, and CSF), to determine the best predictors of episodic memory impairment in PD.
|
31054380 |
2019 |
|
Memory impairment
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
We used linear regression, which included imaging and clinical measures (age, duration, education, gender, and CSF), to determine the best predictors of episodic memory impairment in PD.
|
31054380 |
2019 |
|
Forgetful
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
We used linear regression, which included imaging and clinical measures (age, duration, education, gender, and CSF), to determine the best predictors of episodic memory impairment in PD.
|
31054380 |
2019 |
|
Tuberculosis, Meningeal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We used <sup>1</sup>H nuclear magnetic resonance-based metabolomics to investigate the metabolic features of the CSF from 18 TBM and 20 VM patients.
|
28063937 |
2017 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We use a three-phase level set formulation of segmentation and bias field estimation to segment MS lesions and normal tissue region (including GM and WM) and CSF and the background from FLAIR images.
|
28522366 |
2018 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We transduced the human glioblastoma cell line D54MG in vitro with genes encoding the proinflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), the T cell co-stimulatory molecule B7-2, or both (in a bicistronic vector) via retroviral vectors.
|
9189765 |
1997 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
We transduced the human glioblastoma cell line D54MG in vitro with genes encoding the proinflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), the T cell co-stimulatory molecule B7-2, or both (in a bicistronic vector) via retroviral vectors.
|
9189765 |
1997 |
|
Adult Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
We transduced the human glioblastoma cell line D54MG in vitro with genes encoding the proinflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), the T cell co-stimulatory molecule B7-2, or both (in a bicistronic vector) via retroviral vectors.
|
9189765 |
1997 |
|
Childhood Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
We transduced the human glioblastoma cell line D54MG in vitro with genes encoding the proinflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), the T cell co-stimulatory molecule B7-2, or both (in a bicistronic vector) via retroviral vectors.
|
9189765 |
1997 |
|
Graft-vs-Host Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
We thus describe a feed-forward cascade whereby GM-CSF-secreting donor T cells accumulate and drive alloantigen presentation in the colon to amplify GVHD severity.
|
31585949 |
2019 |
|
Myeloid Leukemia, Chronic
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We therefore investigated the role of TNF-α and found that it supports survival of CML SPCs by promoting nuclear factor κB/p65 pathway activity and expression of the interleukin 3 and granulocyte/macrophage-colony stimulating factor common β-chain receptor.
|
24041577 |
2013 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We therefore investigated the CSF biomarkers in 18F-florbetaben amyloid-negative positron-emission tomography (PET) [amyloid PET(-)] iNPH, amyloid-positive PET [amyloid PET(+)] AD, and cognitively normal (CN) subjects.
|
31286708 |
2019 |
|
Idiopathic normal pressure hydrocephalus (INPH)
|
0.100 |
Biomarker
|
disease |
BEFREE |
We therefore investigated the CSF biomarkers in 18F-florbetaben amyloid-negative positron-emission tomography (PET) [amyloid PET(-)] iNPH, amyloid-positive PET [amyloid PET(+)] AD, and cognitively normal (CN) subjects.
|
31286708 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We therefore determined the steady-state mRNA expression of five tyrosine kinase receptors, epidermal growth factor receptor (EGF-R), c-met, nerve growth factor receptor (NGF-R), colony-stimulating factor receptor (CSF-R) and c-kit, in eleven human melanoma cell lines with different metastatic potentials in nude mice.
|
7847808 |
1995 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We then assayed these 26 metabolites in serum samples from two well-characterized longitudinal cohorts representing prodromal (Alzheimer's Disease Neuroimaging Initiative [ADNI], N = 767, mean age = 75.19, % female = 42.63) and preclinical (BLSA) (N = 207, mean age = 78.68, % female = 42.63) AD, in which we tested their associations with magnetic resonance imaging (MRI) measures of AD-related brain atrophy, cerebrospinal fluid (CSF) biomarkers of AD pathology, risk of conversion to incident AD, and trajectories of cognitive performance.
|
29370177 |
2018 |
|
CNS disorder
|
0.030 |
Biomarker
|
group |
BEFREE |
We tested this probe in models relevant to the clinical diagnosis and treatment of central nervous system (CNS) diseases that affect CSF flow.
|
31290330 |
2019 |